Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.56 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.56 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KHK | P50053 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1417250 | 0.95 | MAPK14 (0.60) | MAPK14MAPK11FGFR1SRCFGFR2 | |
| SCHEMBL1382961 | 0.92 | MAPK14 (0.58) | MAPK14MAPK11FGFR1SRCFGFR2 | |
| SCHEMBL1382334 | 0.92 | MAPK14 (0.58) | MAPK14MAPK11FGFR1SRCFGFR2 | |
| SCHEMBL1416991 | 0.92 | MAPK14 (0.60) | MAPK14MAPK11FGFR1SRCFGFR2 | |
| SCHEMBL1386561 | 0.91 | MAPK14 (0.57) | MAPK14MAPK11FGFR1SRCFGFR2 | |
| SCHEMBL1383451 | 0.91 | MAPK14 (0.57) | MAPK14MAPK11FGFR1SRCFGFR2 | |
| SCHEMBL1417010 | 0.91 | MAPK14 (0.57) | MAPK14MAPK11FGFR1SRCFGFR2 | |
| SCHEMBL1383736 | 0.91 | MAPK14 (0.66) | MAPK14MAPK11 | |
| SCHEMBL1385590 | 0.91 | MAPK14 (0.54) | MAPK14MAPK11FGFR1SRCFGFR2 | |
| SCHEMBL1383414 | 0.91 | MAPK14 (0.56) | MAPK14MAPK11FGFR1SRCFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1832928-B | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2012-07-04 | — | — | CN | claimed |
| JP-4838121-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-1641764-B1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |
| CN-1832928-A | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2006-09-13 | — | — | CN | claimed |
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MEREO BIOPHARMA 1 LIMINTED (GB) | 2005-03-03 | — | — | US | claimed |
| US-11701341-B2 | Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease | MEREO BIOPHARMA 1 LIMITED (GB) | 2023-07-18 | — | — | US | disclosed |
| US-11234967-B2 | Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease | MEREO BIOPHARMA 1 LIMITED (GB) | 2022-02-01 | — | — | US | disclosed |
| US-11129810-B2 | Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease | MEREO BIOPHARMA 1 LIMITED (GB) | 2021-09-28 | — | — | US | disclosed |
| US-20200383950-A1 | USE OF 3-[5-AMINO-4-(3-CYANOBENZOYL)-PYRAZOL-1-YL]-N-CYCLOPROPYL-4-METHYLBENZAMIDE IN THE PREVENTION OR REDUCTION OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | MEREO BIOPHARMA 1 LIMITED (GB) | 2020-12-10 | — | — | US | disclosed |
| US-20200352909-A1 | USE OF 3-[5-AMINO-4-(3-CYANOBENZOYL)-PYRAZOL-1-YL]-N-CYCLOPROPYL-4-METHYLBENZAMIDE IN THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | MEREO BIOPHARMA 1 LIMITED (GB) | 2020-11-12 | — | — | US | disclosed |
| US-20200281896-A1 | DOSAGE REGIMEN FOR THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | MEREO BIOPHARMA 1 LIMITED (GB) | 2020-09-10 | — | — | US | disclosed |
| US-10617674-B2 | Dosage regimen for the treatment of acute exacerbations of inflammatory conditions | MEREO BIOPHARMA 1 LIMITED (GB) | 2020-04-14 | — | — | US | disclosed |
| EP-2298743-A1 | 5-membered heterocycle-based P38 kinase inhibitors | Novartis AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-7863314-B2 | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2011-01-04 | — | — | US | disclosed |
| US-7863314-B2 | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2011-01-04 | — | — | US | disclosed |
| US-7863314-B2 | 5-membered heterocycle-based p38 kinase inhibitors | NOVARTIS AG (CH) | 2011-01-04 | — | — | US | disclosed |
| WO-2007096151-A2 | INHIBITORS OF P38-KINASE FOR TREATMENT OF PULMONARY HYPERTENSION | NOVARTIS AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| EP-1641764-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | Novartis AG (CH) | 2006-04-05 | — | — | EP | disclosed |
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MEREO BIOPHARMA 1 LIMINTED (GB) | 2005-03-03 | — | — | US | disclosed |
| WO-2005009973-A1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11129810-B2 | Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease | CCL11, CHRM3, EDNRB | MAPK14 1329/4885MAPK11 1334/4885FGFR1 4023/4885 |
| US-20200352909-A1 | USE OF 3-[5-AMINO-4-(3-CYANOBENZOYL)-PYRAZOL-1-YL]-N-CYCLOPROPYL-4-METHYLBENZAMIDE IN THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | EPX, ELANE, SERPINB1 | MAPK14 1822/4885MAPK11 2799/4885FGFR1 4274/4885 |
| US-20050049288-A1 | 5-MEMBERED HETEROCYCLE-BASED p38 KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K8 | MAPK14 33/4885MAPK11 38/4885FGFR1 1029/4885 |
| US-11234967-B2 | Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease | CHRM3, PDE3B, PDE3A | MAPK14 2307/4885MAPK11 2468/4885FGFR1 4113/4885 |
| US-10617674-B2 | Dosage regimen for the treatment of acute exacerbations of inflammatory conditions | CCL11, IL5, ELANE | MAPK14 1692/4885MAPK11 1777/4885FGFR1 2983/4885 |
| US-20200383950-A1 | USE OF 3-[5-AMINO-4-(3-CYANOBENZOYL)-PYRAZOL-1-YL]-N-CYCLOPROPYL-4-METHYLBENZAMIDE IN THE PREVENTION OR REDUCTION OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | CHRM3, PDE3B, PDE3A | MAPK14 2307/4885MAPK11 2468/4885FGFR1 4113/4885 |
| US-11701341-B2 | Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease | EPX, ELANE, SERPINB1 | MAPK14 1822/4885MAPK11 2799/4885FGFR1 4274/4885 |
| US-20200281896-A1 | DOSAGE REGIMEN FOR THE TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | CCL11, CHRM3, EDNRB | MAPK14 1329/4885MAPK11 1334/4885FGFR1 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.